There is high unmet medical needs metastatic melanoma, with a 5 years survival rate at stage IV of 15-20%. Immunotherapy gives between 15 and 30% of responses. Anti-BRAF treatments trigger resistance within a couple of months and there is no efficient alternatives.
Products in development are mainly BRAF/MEK/ERK and PI3K/AkT/mTOR inhibitors. New products targeting other signaling pathways are needed in order to address efficiently melanoma resistance.
GlobalData 2023 market forecast for melanoma is $5.64 billion.
HOW IT WORKS
•There is increasing evidence that AMPK signaling is key to stop cancer growth.
•The novel compound family is capable of activating AMPK signaling pathway. This results in tumor growth inhibition.
•Very promising results in vivo with the best compound (CRO15)
KEY BENEFITS vs. STATE OF THE ART
On-going development funded by SATT :
•Hit to Lead optimization
•Target and off-target studies
•Safety and tolerability studies
Melanoma and metastatic melanoma (B-Raf mutated and wild type)
Other solid tumors